-
1
-
-
13444256401
-
Efficacy of lenalidomide in myelodysplastic syndromes
-
List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
-
(2005)
N Engl J Med
, vol.352
, pp. 549-557
-
-
List, A.1
Kurtin, S.2
Roe, D.J.3
Buresh, A.4
Mahadevan, D.5
Fuchs, D.6
-
2
-
-
33749438404
-
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
-
List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
-
(2006)
N Engl J Med
, vol.355
, pp. 1456-1465
-
-
List, A.1
Dewald, G.2
Bennett, J.3
Giagounidis, A.4
Raza, A.5
Feldman, E.6
-
4
-
-
34247337635
-
Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion
-
Martin J., Andrea P., Ann-Mari F., Emma K.E., Mats M., Jan S., et al. Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion. Blood 106 (2005) 960a
-
(2005)
Blood
, vol.106
-
-
Martin, J.1
Andrea, P.2
Ann-Mari, F.3
Emma, K.E.4
Mats, M.5
Jan, S.6
-
5
-
-
23944489636
-
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
-
Giagounidis A.A., Germing U., Strupp C., Hildebrandt B., Heinsch M., and Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84 (2005) 569-571
-
(2005)
Ann Hematol
, vol.84
, pp. 569-571
-
-
Giagounidis, A.A.1
Germing, U.2
Strupp, C.3
Hildebrandt, B.4
Heinsch, M.5
Aul, C.6
-
6
-
-
38049113182
-
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
-
Raza A., Reeves J.A., Feldman E.J., Dewald G.W., Bennett J.M., Deeg H.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111 (2008) 86-93
-
(2008)
Blood
, vol.111
, pp. 86-93
-
-
Raza, A.1
Reeves, J.A.2
Feldman, E.J.3
Dewald, G.W.4
Bennett, J.M.5
Deeg, H.J.6
-
7
-
-
33748205495
-
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
-
Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108 (2006) 1497-1503
-
(2006)
Blood
, vol.108
, pp. 1497-1503
-
-
Tefferi, A.1
Barosi, G.2
Mesa, R.A.3
Cervantes, F.4
Deeg, H.J.5
Reilly, J.T.6
-
8
-
-
65449150965
-
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
-
Adès L., Boehrer S., Prebet T., Beyne-Rauzy O., Legros L., Ravoet C., et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 113 (2009) 3947-3952
-
(2009)
Blood
, vol.113
, pp. 3947-3952
-
-
Adès, L.1
Boehrer, S.2
Prebet, T.3
Beyne-Rauzy, O.4
Legros, L.5
Ravoet, C.6
-
9
-
-
33845692628
-
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
-
Giagounidis A.A., Haase S., Heinsch M., Gohring G., Schlegelberger B., and Aul C. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol 86 (2007) 133-137
-
(2007)
Ann Hematol
, vol.86
, pp. 133-137
-
-
Giagounidis, A.A.1
Haase, S.2
Heinsch, M.3
Gohring, G.4
Schlegelberger, B.5
Aul, C.6
-
10
-
-
33745961875
-
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
-
Chang D.H., Liu N., Klimek V., Hassoun H., Mazumder A., Nimer S.D., et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108 (2006) 618-621
-
(2006)
Blood
, vol.108
, pp. 618-621
-
-
Chang, D.H.1
Liu, N.2
Klimek, V.3
Hassoun, H.4
Mazumder, A.5
Nimer, S.D.6
-
11
-
-
0033168605
-
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
-
Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163 (1999) 380-386
-
(1999)
J Immunol
, vol.163
, pp. 380-386
-
-
Corral, L.G.1
Haslett, P.A.2
Muller, G.W.3
Chen, R.4
Wong, L.M.5
Ocampo, C.J.6
-
12
-
-
60849118093
-
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality
-
Mesa R.A., Hanson C.A., Ketterling R.P., Schwager S., Knudson R.A., and Tefferi A. Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. Blood 113 (2009) 1200-1201
-
(2009)
Blood
, vol.113
, pp. 1200-1201
-
-
Mesa, R.A.1
Hanson, C.A.2
Ketterling, R.P.3
Schwager, S.4
Knudson, R.A.5
Tefferi, A.6
-
13
-
-
10744229499
-
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
-
Giagounidis A.A., Germing U., Haase S., Hildebrandt B., Schlegelberger B., Schoch C., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18 (2004) 113-119
-
(2004)
Leukemia
, vol.18
, pp. 113-119
-
-
Giagounidis, A.A.1
Germing, U.2
Haase, S.3
Hildebrandt, B.4
Schlegelberger, B.5
Schoch, C.6
-
14
-
-
34848904494
-
Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation
-
Gupta R., Soupir C.P., Johari V., and Hasserjian R.P. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 139 (2007) 265-268
-
(2007)
Br J Haematol
, vol.139
, pp. 265-268
-
-
Gupta, R.1
Soupir, C.P.2
Johari, V.3
Hasserjian, R.P.4
|